



## Docket No.: BM45339 PCT/EP99/09560

## DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

## POLYPEPTIDES AND POLYNUCLEOTIDES "BASB040" FROM NEISSERIA MENINGITIDIS AND VACCINE COMPRISING SAID POLYPEPTIDES AND POLYNECLEOTIDES

the spec	cification of which is attached hereto was filed on and was amended	o. 2 December 1999	as Serial No. PCT/EP99/0	
I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.				
I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, Section 1.56.				
I hereby claim foreign priority benefits under Title 35, United States Code, Section 119(a)-(d) or Section 365(b) of any foreign application(s) for patent or inventor's certificate, or Section 365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or Inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed.				
Prior Fo Number 982688		(s) Country Great Britain	Filing Date 07 December 1998	Priority Claimed Yes
I hereby claim the benefit under Title 35, United States Code, Section 119(e) of any United States provisional application(s) listed below.				
Applic	ation Number	Filing Date		
applica listed b	tion(s) or Section a elow and, insofar a prior United States	365(c) of any PCT Internate as the subject matter of each or PCT International applications applies.	tes Code, Section 120 of an ional application designation hof the claims of this application in the manner provide 12, I acknowledge the duty	g the United States, cation is not disclosed ed by the first

which is material to patentability as defined in Title 37, Code of Federal Regulations, Section 1.56 which became available between the filing date of the prior application and the national or PCT

Status

international filing date of this application.

Filing Date

Serial No.





I hereby appoint the practitioners associated with the Customer Number provided below to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and direct that all correspondence be addressed to that Customer Number:

Customer Number 25,308

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full Name of Inventor:

Jean-Louis RUELLE

Inventor's Signature:

Residence: Rixensart, Belgium

Citizenship:

Belgian

Post Office Address:

GlaxoSmithKline

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, Pennsylvania 19406-0939